Targets of autoantibodies in acquired hemophilia A are not restricted to factor VIII: data from the GTH-AH 01/2010 study

  • Olga Oleshko
    1Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
  • Sonja Werwitzke
    1Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
  • Annika Klingberg
    1Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
  • Torsten Witte
    2Department of Rheumatology and Clinical Immunology, Hannover Medical School, Hannover, Germany
  • Hermann Eichler
    3Institute of Clinical Hemostaseology and Transfusion Medicine, Saarland University and Saarland University Hospital, Homburg/Saar, Germany
  • Robert Klamroth
    4Department of Internal Medicine, Vivantes Clinic Friedrichshain, Berlin, Germany
  • Katharina Holstein
    5Department of Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
  • Christina Hart
    6Department of Hematology and Oncology, University Hospital Regensburg, Regensburg, Germany
  • Christian Pfrepper
    7Division of Hemostaseology, Medical Department I, University Hospital Leipzig, Leipzig, Germany
  • Paul Knöbl
    8Department of Hematology and Hemostasis, Vienna Medical University, Vienna, Austria
  • Richard Greil
    9Salzburg Cancer Research Institute-Center for Clinical Cancer and Immunology Trials, Salzburg, Austria
  • Peter Neumeister
    12Division of Hematology, Medical University, Graz, Austria
  • Birgit M. Reipert
    13IMC University of Applied Sciences, Krems, Austria
  • Andreas Tiede
    1Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany

抄録

<jats:title>Abstract</jats:title> <jats:p>The root cause of autoantibody formation against factor VIII (FVIII) in acquired hemophilia A (AHA) remains unclear. We aimed to assess whether AHA is exclusively associated with autoantibodies toward FVIII or whether patients also produce increased levels of autoantibodies against other targets. A case-control study was performed enrolling patients with AHA and age-matched controls. Human epithelial cell (HEp-2) immunofluorescence was applied to screen for antinuclear (ANA) and anticytoplasmic autoantibodies. Screening for autoantibodies against extractable nuclear antigens was performed by enzyme immunoassay detecting SS-A/Ro, SS-B/La, U1RNP, Scl-70, Jo-1, centromere B, Sm, double-stranded DNA, and α-fodrin (AF). Patients with AHA were more often positive for ANA than control patients (64% vs 30%; odds ratio [OR] 4.02, 1.98-8.18) and had higher ANA titers detected than controls. Cytoplasmic autoantibodies and anti-AF immunoglobulin A autoantibodies were also more frequent in patients with AHA compared with controls. Autoantibodies against any target other than FVIII were found in 78% of patients with AHA compared with 46% of controls (OR 4.16, 1.98-8.39). Results were similar preforming sensitivity analyses (excluding either subjects with autoimmune disorders, cancer, pregnancy, or immunosuppressive medication at baseline) and in multivariable binary logistic regression. To exclude that autoantibody staining was merely a result of cross-reactivity of anti-FVIII autoantibodies, we tested a mix of 7 well-characterized monoclonal anti-FVIII antibodies. These antibodies did not stain HEp-2 cells used for ANA detection. In conclusion, a diverse pattern of autoantibodies is associated with AHA, suggesting that a more general breakdown of immune tolerance might be involved in its pathology.</jats:p>

収録刊行物

  • Blood Advances

    Blood Advances 7 (1), 122-130, 2023-01-10

    American Society of Hematology

被引用文献 (1)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ